Response to "Limitations of the Hazard Ratio as a Summary Measure in Cancer Clinical Trials"

J Thorac Oncol. 2021 Oct;16(10):e87-e88. doi: 10.1016/j.jtho.2021.08.001.

¹ Department of Clinical Research, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, People's Republic of China.
² Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, People's Republic of China.
³ Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, People's Republic of China. Electronic address: zhangli@sysucc.org.cn.
⁴ Jiangsu Hengrui Pharmaceuticals Co. Ltd., Shanghai, People's Republic of China.

No abstract available

Publication types